ContributorsPublishersAdvertisers

Rampal

onclive.com

Dr. Rampal on the Future Research of CDK4/6 Inhibitors in MPNs

Raajit K. Rampal, MD, PhD, discusses the future research of CDK4/6 inhibitors in myeloproliferative neoplasms. Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the future research of CDK4/6 inhibitors in myeloproliferative neoplasms (MPNs). Three CDK4/6 inhibitors—abemaciclib (Verzenio), palbociclib (Ibrance) and ribociclib (Kisqali)—are currently approved by...
onclive.com

Dr. Rampal on Pelabresib With or Without Ruxolitinib in Myelofibrosis

Raajit K. Rampal, MD, PhD, discusses the investigation of pelabresib with or without ruxolitinib in patients with myelofibrosis. Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the investigation of pelabresib (CPI-0610) with or without ruxolitinib (Retuxan) in patients with myelofibrosis. The phase 1/2 MANIFEST trial...
onclive.com

Dr. Rampal on the Potential Utilization of Navtemadlin in Relapsed/Refractory AML and MPNs

Raajit K. Rampal, MD, PhD, discusses the potential utilization of navtemadlin in relapsed/refractory acute myeloid leukemia and patients with blast phase myeloproliferative neoplasm in a phase 1b/2 trial. Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential utilization of navtemadlin (KRT-232) in relapsed/refractory acute...
Picture for Dr. Rampal on the Potential Utilization of Navtemadlin in Relapsed/Refractory AML and MPNs
onclive.com

Dr. Rampal on the Investigation of Navtemadlin in Relapsed/Refractory and MPN

Raajit K. Rampal, MD, PhD, discusses the investigation of navtemadlin in relapsed/refractory acute myeloid leukemia and patients with blast phase myeloproliferative neoplasm in a phase 1b/2 trial. Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the investigation of navtemadlin (KRT-232) in relapsed/refractory acute myeloid leukemia...
onclive.com

Dr. Rampal on the Importance of Risk Stratification in Myelofibrosis

Raajit K. Rampal, MD, PhD, discusses the importance of risk stratification in myelofibrosis. Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the importance of risk stratification in myelofibrosis. Risk stratification with available scoring systems can inform whether a patient with myelofibrosis will derive a sustained...
onclive.com

Dr. Rampal on the Importance of Genomic Testing in Myelofibrosis

Raajit K. Rampal, MD, PhD, discusses the importance of genomic testing in myelofibrosis. Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the importance of genomic testing in myelofibrosis. The JAK inhibitors ruxolitinib (Jakafi) and fedratinib (Inrebic) have transformed the treatment paradigm of myelofibrosis, Rampal says....